Your browser does not support SVG.
  • HOME
  • PIPELINE
  • LEADERSHIP
    Management TeamBoard of Directors
  • DISEASES
    Acne vulgarisAtopic dermatitisHyperhidrosisPsoriasisVitiligo
  • NEWS
  • CAREERS
  • CONTACT

RVT-502

RVT-502

December 3, 2019

Dermavant Announces First Patient Dosed in Phase 2 ...

Read More

December 6, 2018

Dermavant Sciences to Present New Data on Cerdulat ...

Read More

Recent Posts

  • Dermavant Named One of Fortune® Magazine’s 2020 “100 Best Small and Medium Companies to Work For”

  • Dermavant’s Pivotal Phase 3 PSOARING Data for Tapinarof Cream in Adults with Plaque Psoriasis Selected as Late-Breaking Oral Presentation at the 29th European Academy of Dermatology and Venereology (EADV) Virtual Congress

  • Dermavant Announces Presentation of Tapinarof Pivotal Phase 3 PSOARING Data at Fall Clinical Dermatology Conference

  • Dermavant Reports Positive Phase 3 Results for Tapinarof Cream in Adult Patients with Plaque Psoriasis

  • Dermavant Announces Publication in JAAD of Secondary Efficacy and Patient-Reported Outcomes in Phase 2b Clinical Trial of Tapinarof Cream for the Treatment of Atopic Dermatitis

Archives

  • November 2020
  • October 2020
  • August 2020
  • June 2020
  • May 2020
  • April 2020
  • January 2020
  • December 2019
  • June 2019
  • May 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • April 2018
  • September 2017
  • July 2017
  • December 2016
  • November 2015

Categories

  • Dermavant Sciences
  • News
  • RVT-201
  • RVT-501
  • RVT-502
  • RVT-504
  • Tapinarof
  • Home
  • Pipeline
  • Leadership
    Management TeamBoard of Directors
  • Diseases
    Acne vulgarisAtopic dermatitisHyperhidrosisPsoriasisVitiligo
  • News
  • Careers
  • Contact

Copyright © 2021 Dermavant Sciences, Inc. All rights reserved.
Privacy Policy    |   Terms of Use